×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BIIB – biogen inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BIIB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
08:27 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Mizuho from $251.00 to $207.00. They now have an "outperform" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Mizuho from $251.00 to $207.00. They now have an "outperform" rating on the stock.
11/20
02:02 pm
biib
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside [Yahoo! Finance]
Low
Report
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside [Yahoo! Finance]
11/19
01:13 am
biib
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity [Yahoo! Finance]
Low
Report
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity [Yahoo! Finance]
11/19
01:00 am
biib
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
Low
Report
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
11/18
07:21 am
biib
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Needham & Company LLC to a "hold" rating. They now have a $270.00 price target on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Needham & Company LLC to a "hold" rating. They now have a $270.00 price target on the stock.
11/18
07:12 am
biib
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ [Yahoo! Finance]
Low
Report
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ [Yahoo! Finance]
11/18
04:37 am
biib
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? [Yahoo! Finance]
Low
Report
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? [Yahoo! Finance]
11/15
10:59 am
biib
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe [Yahoo! Finance]
Low
Report
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
01:25 pm
biib
Form SC 13G/A BIOGEN INC. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A BIOGEN INC. Filed by: VANGUARD GROUP INC
11/7
04:28 pm
biib
Form 4 BIOGEN INC. For: Nov 05 Filed by: ALEXANDER SUSAN H
Low
Report
Form 4 BIOGEN INC. For: Nov 05 Filed by: ALEXANDER SUSAN H
11/4
04:39 pm
biib
Form 4 BIOGEN INC. For: Nov 01 Filed by: Grogan Jane
Low
Report
Form 4 BIOGEN INC. For: Nov 01 Filed by: Grogan Jane
11/4
11:20 am
biib
Form SC 13G/A BIOGEN INC. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A BIOGEN INC. Filed by: VANGUARD GROUP INC
10/30
04:46 pm
biib
Form 8-K BIOGEN INC. For: Oct 28
Medium
Report
Form 8-K BIOGEN INC. For: Oct 28
10/30
04:32 pm
biib
Form 10-Q BIOGEN INC. For: Sep 30
Medium
Report
Form 10-Q BIOGEN INC. For: Sep 30
10/30
06:56 am
biib
Form 8-K BIOGEN INC. For: Oct 30
Medium
Report
Form 8-K BIOGEN INC. For: Oct 30
10/16
12:12 pm
biib
Form SC 13G BIOGEN INC. Filed by: STATE STREET CORP
Low
Report
Form SC 13G BIOGEN INC. Filed by: STATE STREET CORP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/22
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
25.3%
2/5 Form SC 13G/A BIOGEN INC. Filed by: BlackRock Inc. 17.6%
3/12 Form 4 BIOGEN INC. For: Mar 11 Filed by: SHERWIN STEPHEN A 15.1%
3/16 Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World 8.4%
3/2 Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. 6.2%
7/23 Biogen profit rises 72% on multiple sclerosis therapy sales [Reuters] 4.7%
4/2 Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study 4.3%
3/3 Why Biogen Stock Rose 14.7% in February [The Motley Fool] 4.0%
2/3 Form 8-K BIOGEN INC. For: Jan 28 3.9%
11/22 Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) 3.7%
2/5 Form SC 13G/A BIOGEN INC. Filed by: BlackRock Inc. 17.6%
3/12 Form 4 BIOGEN INC. For: Mar 11 Filed by: SHERWIN STEPHEN A 15.1%
3/16 Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World 8.4%
3/2 Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. 6.2%
7/23 Biogen profit rises 72% on multiple sclerosis therapy sales [Reuters] 4.7%
4/2 Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study 4.3%
3/3 Why Biogen Stock Rose 14.7% in February [The Motley Fool] 4.0%
2/3 Form 8-K BIOGEN INC. For: Jan 28 3.9%
11/22 Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) 3.7%
TOP News Decliners
10/22
Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process [MarketWatch]
-11.9%
2/5 U.S. patent office rules in favor of Biogen over Mylan for MS drug [Reuters] -9.1%
3/7 Is Biogen Inc. (BIIB) A Good Stock To Buy? [Yahoo! Finance News] -5.7%
4/22 Q1/2020 3/31/2020 EPS 9.140 ZacksConsensus 7.740 ActVsEst 1.400 - Beat -5.1%
2/27 Biogen Inc (NASDAQ: BIIB) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -4.9%
3/18 Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)] -4.5%
1/30 Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters] -4.0%
10/23 Biogen Inc (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $212.00 to $262.00. They now have an "underweight" rating on the stock. -3.5%
1/30 Biogen Inc (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Wedbush. -3.2%
10/2 Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders -3.1%
2/5 U.S. patent office rules in favor of Biogen over Mylan for MS drug [Reuters] -9.1%
3/7 Is Biogen Inc. (BIIB) A Good Stock To Buy? [Yahoo! Finance News] -5.7%
4/22 Q1/2020 3/31/2020 EPS 9.140 ZacksConsensus 7.740 ActVsEst 1.400 - Beat -5.1%
2/27 Biogen Inc (NASDAQ: BIIB) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -4.9%
3/18 Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)] -4.5%
1/30 Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters] -4.0%
10/23 Biogen Inc (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $212.00 to $262.00. They now have an "underweight" rating on the stock. -3.5%
1/30 Biogen Inc (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Wedbush. -3.2%
10/2 Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: